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Introduction
Cutaneous adverse drug reactions are
amongst common conditions seen in
Dermatology. An adverse drug
reaction may be defined as an
undesirable clinical manifestation
resulting from administration of a
particular drug; this includes reactions
due to overdose, predictable side-
effects and unanticipated adverse
manifestations.  Adverse drug
reactions may be said to be the
inevitable price we pay for the benefits
of modern drug therapy. Some drug
reactions cause minor symptoms to
patients whilst others are l i fe
threatening, thus they are costly both
in terms of the human illness caused
and in economic terms, and can
undermine the doctor-pat ient
relationship. In this article I am briefly




This is by far the commonest form of
cutaneous reaction to a drug. 1 It may
develop within hours to days after drug
admin is t ra t ion,  and may be
accompanied by fever, pruritus and
eosinophilia. The clinical features are
variable, the lesions may be
scar lat in i form, rubel l i form or
mobilliform, or may consist of a diffuse
eruption of erythematous macules and
papules (Figure 1). The distribution is
variable, but it is generally symmetrical,
occurring commonly on the trunk and
extremities. Any drug can cause this
kind of cutaneous reaction. Treatment
involves stopping the offending drug
and a short course of systemic steroids
may be helpful. Topical steroids and
emollients should be applied.
Antihistamines should be added to
relieve pruritus.
2. Erythroderma
Erythroderma is the term applied to
any inflammatory skin disease, which
affects more than 90% of the body
surface with erythema and scaling.
Although it usually occurs as a
complication of several inflammatory
skin diseases, drugs are also a major
cause. It may or may not follow
exanthematic eruptions. Drug induced
erythroderma usually starts days to
weeks following ingestion of a drug,
with widespread erythema followed
by extensive exfoliation, hence the
term exfoliative dermatitis is often used
(Figure 2a and 2b).
In erythroderma normal skin barrier
function is disrupted and l i fe
threatening complications may occur
e.g. septicaemia, hypothermia,
dehydra t ion  and e lec t ro ly te
imbalances. Several drugs have been
implicated in erythroderma, and these
include antibiotics, anticonvulsants,
antipsychotics and NSAIDS. Patients
with erythroderma from whatever
cause are better treated as in-patients.
In drug induced erythroderma the
offending drug must be stopped
immediately. A short course of
systemic steroids is administered to
get the patient out of the acute crisis.
Topical steroids and emollients should
be applied. Antibiotics may be
Figure 1: Maculopapular rash due to
amoxicillin
Figure 2a: Erythroderma due to
carbamazepine in an epileptic patient
Figure 2b: Close-up view, note marked
erythema and scaling
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necessary for secondary bacterial
infections. Other supportive measures
include maintenance of fluid and
electrolyte balance as well as
nutritional support.
3. Drug induced photosensitive
dermatitis
This is a drug-light reaction, which
causes eruptions on sun exposed
areas of the body, thus the face, upper
part of the chest, and extensor aspects
of the arms. This reaction may be
phototoxic or photo-allergic. Phototoxic
reaction can be produced in almost
all individuals given high dose of a
drug and sufficient light irradiation.
Photo-allergic reactions require a latent
period during which sensitization
occurs, and usually appear within 24
hours of re-exposure to drug and light
in a sensitized individual. Drug
induced photosensitive dermatitis may
present as erythema, blistering,
desquamation and residual hypo- or
hyperpigmentation on sun exposed
areas (Figure 3).
These reactions can occur due to
a n t i b i o t i c s ,  a n t i e p i l e p t i c s ,
antipsychotics, antihypertensives,
NSAIDS and many other groups of
drugs. (It is important to remember
that HIV and connective tissue
diseases are also major causes of
photosensitivity and must always be
excluded). Treatment: Substitute the
offending drug with suitable alternative
and topical steroids should be applied
on affected areas. Sun protection may
be necessary.
4. Fixed drug eruption
This presents as well circumscribed
round to oval slatey-grey macules.
They characteristically recur on the
same sites each time the drug is
administered, with each exposure,
however the number of involved sites
may increase.1,2,3  Lesions may occur
on the trunk, limbs, genitalia, perianal
and perioral areas (Figure 4). Although
fixed drug eruption can be caused by
many drugs, phenolphthalein found
in laxatives is one of the commonest
causes3, thus this condition is seen
more frequently in people who take
laxatives. The offending drug should
be identified and stopped. Potent
topical steroids should be applied,
however hyperpigmentation may
persist for longer periods despite
adequate treatment.
5. Er y thema mul t i fo r me
Erythema multiforme is another
common form of cutaneous drug
reaction. Typical lesions are called
“target lesions”.
These lesions are usually less than
3cm in diameter, rounded, and have
three concentric zones; a central area
of dusky erythema, a middle paler
zone of oedema, and an outer ring of
erythema with a well defined edge.4,5
(Figure 5)  These lesions appear in
successive crops. There may be few
lesions or may be profuse. Classically
the backs of the hands, palms, wrists,
feet and extensor aspect of elbows
are affected.
Patients who present with target
lesions alone are diagnosed as
erythema multiforme minor, whilst
target lesions plus involvement of at
least two mucous membranes
comprise erythema multiforme major
or Stevens-Johnson syndrome (Figure
6). Steven-Johnson syndrome is a
more severe form of erythema
multiforme. The onset is usually
sudden, although there may be a
prodromal systemic illness of 1 – 13
days before the eruption appears.
Numerous organs are affected. In one
review of 81 cases, changes were
found with the following frequency:
mouth 100%, eyes 91%, skin 83%,
male genitalia 57%, anal mucous
membrane 5%, bronchitis 6%,
pneumonitis 23%.4  The mouth and
lips show characteristic haemorrhagic
crusting.6
Patients with Stevens-Johnson
syndrome should ideally be admitted
in hospital. Attention should be paid
to maintenance of fluid and electrolyte
Figure 3: Photosensitive dermatitis, note
the typical distribution on sun-exposed
areas
Figure 4: Fixed drug eruption due to
t r ime thop r im-su l famethoxazo le
Figure 5: Erythema multiforme minor
due to penicillin (Pen VK)
Figure 6: Child with Stevens-Johnson
syndrome due to amoxicillin. Note
mucosal involvement
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balance. Sepsis if any should be
treated accordingly. The use of
systemic steroids in Stevens-Johnson
syndrome is controversial. Topical
steroids and emollients can be
applied. These patients often have
oral mucosal involvement and
therefore unable to feed, therefore
nutritional support is important.
6. Toxic Epidermal Necrolysis
Toxic Epidermal Necrolysis (TEN) is a
severe form of Stevens-Johnson
s y n d ro m e  a s s o c i a t e d  w i t h
considerable morbidity and mortality.4
The condition presents within hours
or days of medication administration
with tenderness on the skin followed
by widespread erythema. The
epidermis becomes necrotic, full
thickness splitting of skin with
denudation occurs.(Figure 7a and 7b).
Buccal, genital, nasal and ophthalmic
mucous membranes are often
involved. The clinical picture of TEN
resembles that of thermal burns and
causes of death are dehydration and
sepsis. Healing of lesions occurs with
scar formation. Ocular complications
occur in 40 – 50% of survivors and
include ectropion, entropion,
synblepharon, corneal opacities and
blindness. There is no specific drug
treatment for this condition. Important
measures include maintenance of fluid
and electrolytes balance prevention
and treatment of sepsis, and wound
dressing. Patients with severe disease
and extensive skin loss should be
transferred to intensive care unit or to
a burns unit, and subsequently
managed as if they were suffering from
thermal burns of the same degree.4
Systemic steroids are not helpful
in TEN. Several groups have
suggested that systemic steroids
should not be used because they
increase mortality due to sepsis.7,8,9
T h e  u s e  o f  i n t r a v e n o u s
immunoglobulins (IVIG) in the
treatment of TEN was first suggested
in 1998, and showed good results in
some centres.10,11 Studies have shown
that early use of IVIG in TEN results in
rapid clinical improvement, shorter
hospital stays and decreased
mortality.10,11,12 Toxic epidermal
necrolysis can occur due to antibiotics,
anticonvulsants, NSAIDS, antifungals
and many other drugs. 1 0 , 1 1 , 1 2
Recently a case of fatal toxic
epidermal  necrolys is  due to
lansoprazole was reported.13 In this
report a patient who previously had
erythema multiforme following intake
of lansoprazole was later inadvertently
prescribed the same drug. This time
he had a fatal toxic epidermal
necrolysis and died. This case
illustrates the perils of rechallenge with
a drug that has previously caused a
skin reaction. Furthermore, it highlights
the need to communicate effectively
about drug sensitivities, both to the
patient and amongst clinicians. Medic
alert bracelets must be mandatory to
reduce the risk of inadvertent drug re-
exposure. 
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Figure 7a: Toxic epidermal necrolysis
due to trimethoprim-sulfamethoxazole
Figure 7b: Toxic epidermal necrolysis
due to ibuprofen
CPD
